A Cleveland Clinic team brewed a storm when their meta-analysis of 42 placebo-controlled studies involving rosiglitazone turned up a significantly increased risk of myocardial infarction and an increase of “borderline significance” in cardiovascular deaths. An accompanying editorial in the New England Journal of Medicine questions whether the drug was approved and used too soon, on the basis of a mere secondary effect (lowering blood glucose). Another in the Lancet urges doctors to wait for further evidence before leaping to judgment.
Is this the letdown after a happy fantasy? Only six months ago, the results of the aptly named DREAM trial were prompting suggestions that the drug might prevent type 2 diabetes.
Refine your search with these clinically useful categories:
Practical Articles and News
In the news category, you can find the safety alert that the Food and Drug Administration swiftly issued in response to the new study.
Evidence-based Articles and Meta-analyses
Critics argue that the FDA approved the drug without sufficient evidence of benefit regarding primary outcomes such as mortality. What does evidence-based research show about the effects of rosiglitazone?
Clinical Trials for Patients
Learn what clinical trials now underway may provide new information about the use of this drug.
Posted by Cranky Aged Mama
